Abstract
Polycystic kidney disease (PKD), the most common genetic cause of chronic renal failure, is characterized by the presence of numerous fluid-filled cysts in renal parenchyma. Despite recent progress, no FDA-approved therapy is available to retard cyst growth. Here, we review current evidence implicating two groups of microRNAs (miRNAs) - the miR-17∼92 cluster and miR-200s - in the pathogenesis of PKD. We present a new hypothesis for cyst growth involving miRNAs and regulation of PKD gene dosage. We propose that manipulating miRNA function in an attempt to normalize PKD gene dosage represents a novel therapeutic strategy in PKD. © 2012 Elsevier Ltd. All rights reserved.
Cite
CITATION STYLE
Noureddine, L., Hajarnis, S., & Patel, V. (2013). MicroRNAs and polycystic kidney disease. Drug Discovery Today: Disease Models. Elsevier Ltd. https://doi.org/10.1016/j.ddmod.2013.10.001
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.